Hematology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hemophilia A
Findings from Emory University, Aflac Cancer Center and Blood Disorders Service provide new insights into hemophilia a
April 16th, 2007
New investigation results, "The humoral response to human factor VIII in hemophilia A mice," are detailed in a study published in Journal of Thrombosis and Haemostasis. According to a study from the United States, "Inhibitory antibodies (Abs) to factor VIII (FVIII inhibitors) constitute the most significant complication in the management of hemophilia A. The analysis of FVIII inhibitors is confounded by polyclonality and the size of FVIII. The goal of this study was to dissect the polyclonal response to human FVIII in hemophilia A mice undergoing a dosage schedule that mimics human use." "Splenic B-cell hybridomas were obtained following serial i.v. injections of...
Source: Hematology Week (2007-04-16)
|
